Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

Precision BioSciences (DTIL)

Precision BioSciences Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:DTIL
DateTimeSourceHeadlineSymbolCompany
29/01/202512:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:DTILPrecision BioSciences Inc
29/01/202512:01Business WirePrecision BioSciences Strengthens Senior Leadership Team to Drive Multiple In Vivo Gene Editing ProgramsNASDAQ:DTILPrecision BioSciences Inc
24/01/202520:10Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:DTILPrecision BioSciences Inc
23/01/202502:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:DTILPrecision BioSciences Inc
23/01/202502:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:DTILPrecision BioSciences Inc
23/01/202502:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:DTILPrecision BioSciences Inc
23/01/202502:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:DTILPrecision BioSciences Inc
22/01/202520:14Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:DTILPrecision BioSciences Inc
22/01/202520:13Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:DTILPrecision BioSciences Inc
21/01/202521:19Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:DTILPrecision BioSciences Inc
09/01/202515:01Business WirePrecision BioSciences Announces Complete Clinical Response in First Infant Dosed by Partner iECURE in Ongoing Phase 1/2 Clinical Trial in Ornithine Transcarbamylase (OTC) DeficiencyNASDAQ:DTILPrecision BioSciences Inc
09/01/202513:00Business WireiECURE Reports Complete Clinical Response in First Infant Dosed with its In Vivo Gene Editing Candidate ECUR-506 in an Ongoing Phase 1/2 Clinical Trial in Ornithine Transcarbamylase (OTC) DeficiencyNASDAQ:DTILPrecision BioSciences Inc
08/01/202513:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:DTILPrecision BioSciences Inc
02/01/202512:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:DTILPrecision BioSciences Inc
31/12/202412:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:DTILPrecision BioSciences Inc
31/12/202412:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:DTILPrecision BioSciences Inc
30/12/202411:10Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:DTILPrecision BioSciences Inc
18/12/202412:01Business WirePrecision BioSciences Receives Approval in Hong Kong to Expand PBGENE-HBV Phase 1 ELIMINATE-B Trial for the Treatment of Chronic Hepatitis BNASDAQ:DTILPrecision BioSciences Inc
21/11/202421:30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:DTILPrecision BioSciences Inc
21/11/202412:01Business WirePrecision BioSciences to Participate in Upcoming November Investor ConferencesNASDAQ:DTILPrecision BioSciences Inc
15/11/202412:00Business WirePrecision BioSciences Highlights Preclinical Data and Outlines Design of First-in-Human Clinical Trial for PBGENE-HBV for Treatment of Chronic Hepatitis BNASDAQ:DTILPrecision BioSciences Inc
06/11/202400:14Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:DTILPrecision BioSciences Inc
06/11/202400:14Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:DTILPrecision BioSciences Inc
06/11/202400:14Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:DTILPrecision BioSciences Inc
04/11/202420:51Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:DTILPrecision BioSciences Inc
04/11/202420:49Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:DTILPrecision BioSciences Inc
04/11/202412:15Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:DTILPrecision BioSciences Inc
04/11/202412:15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:DTILPrecision BioSciences Inc
04/11/202412:01Business WirePrecision BioSciences Reports Third Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:DTILPrecision BioSciences Inc
29/10/202411:01Business WirePrecision BioSciences to Report Third Quarter Results on November 4, 2024NASDAQ:DTILPrecision BioSciences Inc
 Showing the most relevant articles for your search:NASDAQ:DTIL